How to protect the heart and blood vessels – new research

A large American study reported by The Independent found that the drug Mounjaro (tirzepatide) reduces the risk of heart attack by 33% in patients with type 2 diabetes and heart disease. The study involved nearly 53,000 patients: after one year, cardiac complications occurred in 2.9% of the Mounjaro group versus 4.4% in those taking sitagliptin. The therapy also prevented one hospitalization due to infections per 48 patients and one death per 122 people.

A large American study, reported by The Independent, has shown that the drug Mounjaro (tirzepatide), originally developed for treating type 2 diabetes, significantly reduces the risk of cardiovascular complications in patients with diabetes and concomitant heart disease. The study involved nearly 53,000 patients. After one year of follow-up, the risk of cardiac complications in the Mounjaro group was 2.9% versus 4.4% in the sitagliptin group. The likelihood of a heart attack decreased by 33%, although no significant difference in stroke rates was observed. The therapy also helped prevent one hospitalization due to infections per 48 patients and reduced overall mortality—one life saved per 122 people. Mounjaro belongs to the class of GLP-1 receptor agonists and is already used in the UK (NHS) for treating diabetes and obesity. Experts note that real-world clinical data help doctors and patients make more informed decisions when choosing maintenance therapy.